Concepedia

Author

Denis Talbot

Université LavalORCID

Also Known As

D C Talbot, D Talbot, D. C. Talbot, D. Talbot, D.C Talbot, D.C. TALBOT, D.C. Talbot, DC Talbot, Denis C Talbot, Denis C. Talbot

305

Publications

7.1K

Citations

43

H-Index

175

Concepts

All Affiliations

Université LavalChurchill HospitalInstitut National de Santé Publique du QuébecThe Quebec Population Health Research NetworkUniversity of Oxford
DT

About

Denis Talbot is an author at Université Laval specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

42

2K

2

Health Sciences

6

6

280

3

Engineering

5

5

84

4

Natural Sciences

2

2

35

5

Education

1

1

100

Denis Talbot

×

115

Publications

5.8K

Citations

41

H-Index

YearCitations

Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

Ian E. Smith, Mary O’Brien, Denis Talbot,

Journal of Clinical Oncology

2001

311

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski,

Journal of Clinical Oncology

2012

265

A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study

Janie Allaire, Patrick Couture, Myriam Leclerc,

American Journal of Clinical Nutrition

2016

247

Isolation of a small molecule inhibitor of DNA base excision repair

Srinivasan Madhusudan, Frank W. Smart, Paul J. Shrimpton,

Nucleic Acids Research

2005

237

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Srinivasan Madhusudan, Martin D. Foster, S. Muthuramalingam,

Clinical Cancer Research

2004

203

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Michael Wallington, Emma B. Saxon, Martine Bomb,

The Lancet Oncology

2016

186

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

Denis Talbot, Vladimir Moiseyenko, Simon Van Belle,

British Journal of Cancer

2002

180

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial Discussions

Valerie Jenkins, Ivonne Solis‐Trapala, C. Langridge,

Journal of Clinical Oncology

2010

159

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

Danuta M. Skowronski, Yossi Febriani, Solmaz Setayeshgar,

Clinical Infectious Diseases

2022

135

Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours

David Propper, Jeremy Braybrooke, D.J. Taylor,

Annals of Oncology

1999

129

Page 1